NASDAQ:ESRX - Express Scripts Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$92.33 As of 12/20/2018 01:00 AM ET

+0.30 (1.20%)

Get New Express Scripts Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ESRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESRX

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Express Scripts in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $92.33.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Express Scripts. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/5/2018	Mizuho	Set Price Target	Hold	$101.00	Low
11/2/2018	Cowen	Reiterated Rating	Buy	$88.00	Low
11/1/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$83.00 ➝ $90.00	Low
11/1/2018	Royal Bank of Canada	Set Price Target	Buy	$101.00	Medium
11/1/2018	SVB Leerink	Set Price Target	Market Perform ➝ Hold	$95.00 ➝ $100.00	Medium
11/1/2018	Maxim Group	Reiterated Rating	Hold		Low
10/31/2018	William Blair	Downgrade	Outperform ➝ Market Perform		Low
9/18/2018	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$90.00 ➝ $96.50	Low
8/27/2018	Royal Bank of Canada	Boost Price Target	Outperform	$94.00	High
8/1/2018	William Blair	Upgrade	Market Perform ➝ Outperform		Low
7/20/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$81.00	Medium
5/17/2018	Robert W. Baird	Set Price Target	Buy	$92.00	Low
5/3/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $83.00	High
5/3/2018	SVB Leerink	Lower Price Target	Market Perform	$90.00 ➝ $80.00	Medium
3/12/2018	Sanford C. Bernstein	Upgrade	Underperform ➝ Market Perform		Medium
3/9/2018	Wells Fargo & Company	Upgrade	Underperform ➝ Market Perform		Low
3/8/2018	Raymond James	Upgrade	Underperform ➝ Market Perform		Low
3/8/2018	Mizuho	Set Price Target	Hold	$96.00	Low
3/8/2018	William Blair	Downgrade	Outperform ➝ Market Perform		Low
3/8/2018	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$91.00	High
3/8/2018	Maxim Group	Downgrade	Buy ➝ Hold		High
3/8/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$84.00	High
2/28/2018	Maxim Group	Boost Price Target		$87.00 ➝ $101.00	Medium
2/28/2018	Jefferies Financial Group	Set Price Target	Positive ➝ Buy	$91.00	High
2/27/2018	Bank of America	Initiated Coverage	Underperform ➝ Underperform	$77.00	Medium
2/26/2018	Maxim Group	Reiterated Rating	Buy	$87.00	Low
1/31/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$68.00	Low
1/30/2018	Sanford C. Bernstein	Downgrade	Market Perform ➝ Underperform	$55.80 ➝ $77.50	Low
1/24/2018	Mizuho	Set Price Target	Hold	$86.00	Low
1/12/2018	SunTrust Banks	Reiterated Rating	Buy	$95.00	Low
1/9/2018	Robert W. Baird	Reiterated Rating	Outperform ➝ Buy	$81.00 ➝ $92.00	N/A
1/4/2018	Evercore ISI	Initiated Coverage	In ➝ In-Line	$78.00	Low
12/21/2017	SunTrust Banks	Set Price Target	Buy	$86.00	Low
12/21/2017	Needham & Company LLC	Reiterated Rating	Hold		Low
12/15/2017	Jefferies Financial Group	Set Price Target	Buy	$80.00	High
12/15/2017	Royal Bank of Canada	Set Price Target	Hold	$68.00	High
12/15/2017	Raymond James	Reiterated Rating	Sell		Low
12/15/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$72.00 ➝ $81.00	High
12/14/2017	SunTrust Banks	Set Price Target	Buy	$82.00	High
12/14/2017	Maxim Group	Boost Price Target	Buy	$78.00 ➝ $87.00	Low
12/6/2017	Sanford C. Bernstein	Upgrade	Underperform ➝ Market Perform		Low
12/4/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$75.00	High
10/26/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A
10/25/2017	Royal Bank of Canada	Set Price Target	Hold	$66.00	N/A
10/25/2017	Robert W. Baird	Boost Price Target	Neutral	$57.00 ➝ $59.00	N/A
10/24/2017	Mizuho	Set Price Target	Hold	$67.00	N/A
10/9/2017	Raymond James	Reiterated Rating	Market Perform ➝ Underperform		N/A
10/9/2017	UBS Group	Downgrade	Market Perform ➝ Underperform		N/A
9/19/2017	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform	$68.00	High
9/1/2017	Robert W. Baird	Reiterated Rating	Hold	$56.00	Medium
8/29/2017	Jefferies Financial Group	Set Price Target	Buy	$72.00	Low
8/10/2017	Morgan Stanley	Boost Price Target	Underweight	$52.00 ➝ $57.00	Low
7/21/2017	Needham & Company LLC	Initiated Coverage	Hold ➝ Hold		Low
6/9/2017	Cowen	Reiterated Rating	Outperform	$83.00	Low
4/26/2017	Evercore ISI	Lower Price Target	In-Line	$68.50 ➝ $59.00	Medium
4/26/2017	Morgan Stanley	Lower Price Target	Underweight	$71.00 ➝ $52.00	Medium
4/26/2017	Edward Jones	Downgrade	Buy ➝ Hold		High
4/25/2017	Robert W. Baird	Lower Price Target	Neutral	$73.00 ➝ $53.00	High
4/25/2017	UBS Group	Set Price Target	Hold	$71.00	N/A
4/25/2017	SunTrust Banks	Reiterated Rating	Buy		High
4/25/2017	Cowen	Lower Price Target	Outperform	$90.00 ➝ $83.00	High
4/25/2017	Bank of America	Reiterated Rating	Neutral	$77.00	High
4/25/2017	Mizuho	Lower Price Target	Neutral ➝ Neutral	$76.00 ➝ $61.00	High
4/20/2017	Jefferies Financial Group	Set Price Target	Buy	$88.00	Low
4/4/2017	Cowen	Reiterated Rating	Outperform	$90.00	Low
3/29/2017	Argus	Reiterated Rating	Hold		Low
3/18/2017	Jefferies Financial Group	Set Price Target	Buy	$88.00	Low
3/15/2017	Wells Fargo & Company	Downgrade	Market Perform ➝ Underperform		Low
3/8/2017	SVB Leerink	Reiterated Rating	Market Perform	$75.00	Low
3/7/2017	SVB Leerink	Upgrade	Positive		N/A
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	N/A
2/16/2017	Credit Suisse Group	Reiterated Rating	Buy	$85.00	N/A
2/14/2017	Oppenheimer	Reiterated Rating	Hold		N/A
12/16/2016	SVB Leerink	Reiterated Rating	Market Perform		N/A
12/16/2016	Barclays	Reiterated Rating	Overweight		N/A
12/16/2016	Mizuho	Reiterated Rating	Neutral	$76.00	N/A
12/14/2016	Oppenheimer	Reiterated Rating	Hold		N/A
12/1/2016	Sanford C. Bernstein	Reiterated Rating	Underperform	$59.00	N/A
11/3/2016	Deutsche Bank Aktiengesellschaft	Upgrade	Sell ➝ Hold	$69.00 ➝ $70.00	N/A
11/2/2016	Oppenheimer	Reiterated Rating	Market Perform		N/A
10/28/2016	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	N/A
10/5/2016	UBS Group	Initiated Coverage	Neutral	$76.00	N/A
10/3/2016	Credit Suisse Group	Reiterated Rating	Outperform	$85.00	N/A
9/6/2016	Sanford C. Bernstein	Reiterated Rating	Underperform	$68.00	N/A
9/1/2016	SVB Leerink	Reiterated Rating	Market Perform	$80.00	N/A
8/29/2016	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	N/A
8/2/2016	Mizuho	Boost Price Target	Neutral	$77.00 ➝ $82.00	N/A
7/27/2016	Barclays	Boost Price Target	Overweight	$85.00 ➝ $87.00	N/A
7/26/2016	Jefferies Financial Group	Lower Price Target	Buy	$98.00 ➝ $88.00	N/A
7/4/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
6/27/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A

(Data available from 6/21/2016 forward)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Today's Range

Now: $92.33

$92.11

$95.87

50 Day Range

MA: $92.33

$92.33

52 Week Range

Now: $92.33

$66.93

$101.73

Volume

31,612,912 shs

Average Volume

6,636,970 shs

Market Capitalization

$52.06 billion

P/E Ratio

13.00

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Express Scripts?

The following Wall Street sell-side analysts have issued stock ratings on Express Scripts in the last twelve months:
View the latest analyst ratings for ESRX.

What is the current price target for Express Scripts?

0 Wall Street analysts have set twelve-month price targets for Express Scripts in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Express Scripts in the next year.
View the latest price targets for ESRX.

What is the current consensus analyst rating for Express Scripts?

Express Scripts currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ESRX.

What other companies compete with Express Scripts?

Other companies that are similar to Express Scripts include Laboratory Co. of America, Quest Diagnostics, DaVita, Amedisys, Chemed, LHC Group, R1 RCM, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact Express Scripts' investor relations team?

Express Scripts' physical mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company's listed phone number is 314-996-0900 and its investor relations email address is [email protected] The official website for Express Scripts is www.express-scripts.com.